These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Alteration of plasma total F2-isoprostanes before and after hemodialysis in end-stage renal disease patients. Kim KM; Jung BH; Paeng KJ; Kim SW; Chung BC Prostaglandins Leukot Essent Fatty Acids; 2004 May; 70(5):475-8. PubMed ID: 15062851 [TBL] [Abstract][Full Text] [Related]
4. Analysis of monohydroxyeicosatetraenoic acids and F2-isoprostanes as markers of lipid peroxidation in rat brain mitochondria. Wiswedel I; Hirsch D; Nourooz-Zadeh J; Flechsig A; Lück-Lambrecht A; Augustin W Free Radic Res; 2002 Jan; 36(1):1-11. PubMed ID: 11999696 [TBL] [Abstract][Full Text] [Related]
5. Association of plasma F2-isoprostanes and isofurans concentrations with erythropoiesis-stimulating agent resistance in maintenance hemodialysis patients. Rivara MB; Ikizler TA; Ellis CD; Mehrotra R; Himmelfarb J BMC Nephrol; 2015 Jun; 16():79. PubMed ID: 26045064 [TBL] [Abstract][Full Text] [Related]
11. Lipid peroxidation as determined by plasma isoprostanes is related to disease severity in mild asthma. Wood LG; Fitzgerald DA; Gibson PG; Cooper DM; Garg ML Lipids; 2000 Sep; 35(9):967-74. PubMed ID: 11026617 [TBL] [Abstract][Full Text] [Related]
12. Increase in plasma esterified F2-isoprostanes following intravenous iron infusion in patients on hemodialysis. Salahudeen AK; Oliver B; Bower JD; Roberts LJ Kidney Int; 2001 Oct; 60(4):1525-31. PubMed ID: 11576368 [TBL] [Abstract][Full Text] [Related]
13. Plasma F2-isoprostane levels are elevated in chronic hemodialysis patients. Ikizler TA; Morrow JD; Roberts LJ; Evanson JA; Becker B; Hakim RM; Shyr Y; Himmelfarb J Clin Nephrol; 2002 Sep; 58(3):190-7. PubMed ID: 12356187 [TBL] [Abstract][Full Text] [Related]
14. Gamma-tocopherol and docosahexaenoic acid decrease inflammation in dialysis patients. Himmelfarb J; Phinney S; Ikizler TA; Kane J; McMonagle E; Miller G J Ren Nutr; 2007 Sep; 17(5):296-304. PubMed ID: 17720098 [TBL] [Abstract][Full Text] [Related]
15. An improved method for the measurement of urinary and plasma F2-isoprostanes using gas chromatography-mass spectrometry. Mori TA; Croft KD; Puddey IB; Beilin LJ Anal Biochem; 1999 Mar; 268(1):117-25. PubMed ID: 10036170 [TBL] [Abstract][Full Text] [Related]
16. Quantification of F2-isoprostanes by gas chromatography/mass spectrometry as a measure of oxidant stress. Musiek ES; Morrow JD Curr Protoc Toxicol; 2005 Jun; Chapter 17():Unit 17.6. PubMed ID: 23045115 [TBL] [Abstract][Full Text] [Related]
17. Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. Patrono C; FitzGerald GA Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):2309-15. PubMed ID: 9409197 [TBL] [Abstract][Full Text] [Related]
18. F2-isoprostanes as markers of oxidant stress: an overview. Musiek ES; Morrow JD Curr Protoc Toxicol; 2005 Jun; Chapter 17():Unit 17.5. PubMed ID: 23045114 [TBL] [Abstract][Full Text] [Related]
19. Time course and dose response of alpha tocopherol on oxidative stress in haemodialysis patients. Reed A; Cho YJ; Coombes JS; Fassett RG BMC Nephrol; 2009 Oct; 10():32. PubMed ID: 19845969 [TBL] [Abstract][Full Text] [Related]